Sector News

Biotechnology company Relypsa explores potential sale-sources

April 8, 2016
Life sciences

Relypsa Inc, a U.S. maker of treatments for blood disorder hyperkalemia, is exploring a sale following a number of overtures from potential buyers, according to people familiar with the matter.

Relypsa is working with investment bank Centerview Partners Holdings LLC to review offers, the people said. The discussions are in their early stages and may not lead to a sale, the people added, asking not to be identified because the talks are private.

Interest in Relypsa has picked up in recent months after the $2.7 billion sale of ZS Pharma to AstraZeneca Plc, the people said. Relypsa and ZS Pharma are the primary competitors in a race to control the market for hyperkalemia treatment, which some estimates say could be worth more than $6 billion.

Several of the companies that unsuccessfully bid for ZS Pharma have reached out to Relypsa, the people said.

Relypsa declined to comment. Centerview did not respond to a request for comment.

By Carl O’Donnell

Source: Reuters

Related News

May 8, 2021

BD to spin off $1B diabetes care business into standalone public company

Life sciences

BD’s new company will have the freedom to expand its portfolio of tools and technologies for the chronic care of diabetes.

May 8, 2021

Galapagos cuts pipeline, targets €150M in savings after setbacks

Life sciences

The Belgian biotech is pulling out of metabolic diseases and osteoarthritis R&D to focus on its core therapeutic areas.

May 8, 2021

Catalent snares yet another Belgian CDMO to boost fast-growing cell and gene therapy campus

Life sciences

Catalent will use its new facility for commercial production of plasmid DNA, used to make a range of biologics, including viral vectors, mRNA and cell therapies.

Send this to a friend